title: Weekly paclitaxel with concurrent radiotherapy followed by adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma.
abstract: OBJECTIVE
  To evaluate the efficacy and toxicity of weekly paclitaxel with concurrent radiotherapy followed by adjuvant chemotherapy (AC) in patients with locally advanced nasopharyngeal carcinoma (NPC).
  
  
  METHODS
  Between 2004 and 2007, 54 patients with locally advanced NPC were included in this protocol.
  
  
  METHODS
  median age 48; 69% male; 52% World Health Organization (WHO) III; 50% stage III, 50% stage IV. The patients underwent a course of definitive conventional radiotherapy (70 Gy in 7 weeks with 2 Gy/fraction), with concurrent weekly paclitaxel 35 mg/m(2) from the first to the sixth week of radiation. AC was started 4 weeks after the end of the radiotherapy (RT), paclitaxel 135 mg/m(2) on day 1 and cisplatin 30 mg/m(2) on days 1-3 were administered every 4 weeks for two cycles.
  
  
  RESULTS
  Median follow-up was 32 months. Eighty-five percentage of complete response and 15% partial response were achieved at the time of one month after AC. The 3-year actuarial rate of local regional control was 86%; distant metastases-free survival, progression-free survival and overall survival at 3 years were 81%, 69% and 76%, respectively. Forty-nine (91%) patients completed six courses of concurrent chemotherapy with weekly paclitaxel, and 4 (7%) patients delayed at the second cycle of AC. No patient developed severe acute toxicities.
  
  
  CONCLUSIONS
  Weekly paclitaxel with concurrent RT followed by AC is a potentially effective and toxicity tolerable method for locally advanced NPC. Further studies are needed to identify the optimal dose of weekly paclitaxel in this strategy.
authors.affiliation: Radiation Oncology Department, Taizhou Hospital, Wenzhou Medical College, Taizhou, China. huw@tzhospital.com
authors.forename: Wei
authors.initials: W
authors.lastname: Hu
authors.forename: Weijun
authors.initials: W
authors.lastname: Ding
authors.forename: Haihua
authors.initials: H
authors.lastname: Yang
authors.forename: Minghai
authors.initials: M
authors.lastname: Shao
authors.forename: Biyun
authors.initials: B
authors.lastname: Wang
authors.forename: Jianhua
authors.initials: J
authors.lastname: Wang
authors.forename: Sufang
authors.initials: S
authors.lastname: Wu
authors.forename: Shixiu
authors.initials: S
authors.lastname: Wu
authors.forename: Lihui
authors.initials: L
authors.lastname: Jin
authors.forename: Charlie C-M
authors.initials: CC
authors.lastname: Ma
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009303:Nasopharyngeal Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D017239:Paclitaxel / Q000008:administration & dosage*; D011879:Radiotherapy Dosage; D011882:Radiotherapy, High-Energy
chemical_list: D000970:Antineoplastic Agents; D017239:Paclitaxel; D002945:Cisplatin